<h1>Our mission is to restore cell health and resilience through cellular rejuvenation programming to reverse disease, injury, and the disabilities that can occur throughout life.</h1><ul><li>A community of leading scientists, clinicians, and leaders from both academia and industry will work together towards this common mission.</li><li>Altos is based in the US in the San Francisco Bay Area and San Diego, and in the UK in Cambridge.&nbsp;The company also has significant collaborations in Japan.</li><li>The Altos Board of Directors and advisors include Nobel Laureates and scientific leaders.</li></ul>Altos is dedicated to unraveling the deep biology of cellular rejuvenation programming.&nbsp;&nbsp; &nbsp;Altos is designed to integrate the best features of academia and industry -- from academia, the freedom to pursue the most challenging problems in biology, and from industry, the focus on a shared mission, ability to foster deep collaborations, and the passion and commitment to transform science into medicines.The Altos Institutes of Science will pursue deep scientific questions and integrate their findings into one collaborative research effort. The Altos Institute of Medicine will capture knowledge generated about cell health and programming and develop transformative medicines.Together, we are building a company where many of the world’s best scientists can collaborate internally and externally and develop their research with the speed, mission, and focus of private enterprise.&nbsp;Our success will depend upon a culture of intense collaboration, enthusiasm, and openness.

sHome

Dr. Hal Barron is the CEO and Board Co-Chair of Altos Labs.&nbsp;Prior to joining Altos, he was Chief Scientific Officer and President, R&amp;D at GSK, where he was responsible for all research and development activities across the globe including life-cycle management for all marketed products.&nbsp;Dr. Barron remains a non-executive director on GSK’s Board of Directors.Prior to joining GSK, Dr. Barron was President, R&amp;D at Calico LLC (California Life Company), an Alphabet-funded company that uses advanced technologies to increase understanding of lifespan biology. Prior to this role, he was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, Dr. Barron was Senior Vice President of Development and Chief Medical Officer. He was a non-executive director and chair of the Science &amp; Technology Committee at Juno Therapeutics, Inc until March 2018, when it was acquired by Celgene Corporation. He also previously served as a non-executive Board director of GRAIL, Inc until it was acquired by Illumina. He was also an Advisory Board Member of Verily Life Sciences LLC until 2021.Dr. Barron holds a BS in Physics from Washington University in St. Louis and a MD from Yale University. He completed his training in Internal Medicine and Cardiology at the University of California, San Francisco. Dr. Barron has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals. He also continues to teach as an Adjunct Professor of Epidemiology and Biostatistics at the University of California, San Francisco.

Altos-Labs-Hal-Barron

Hal Barron

Co-Chairman

CEO and Founder

Dr. Klausner is currently Founder, Chief Scientist and Board Co-Chairman of Altos Labs. He is also founder and Chairman of Lyell Immunopharma, Inc. He was founder and Director of Juno Therapeutics and founder and Director of GRAIL. He is Chairman of Sonoma Biotherapeutics. Co-Founder and Chairman of Lifemine Therapeutics. He is the former Senior Vice President, Chief Medical Officer and Chief Opportunity Officer of Illumina Corporation. Previously, he was Executive Director for Global Health of the Bill and Melinda Gates Foundation. Dr. Klausner was appointed by Presidents Clinton and Bush as the eleventh Director of the U.S. National Cancer Institute between 1995 and 2001. Dr. Klausner served as chief of the Cell Biology and Metabolism Branch of the National Institute of Child Health and Human Development as well as a past president of the American Society of Clinical Investigation. He has served in senior advisory roles to the US, Norwegian, Qatari and Indian governments.More specific to his own research accomplishments, Dr. Klausner has provided valuable mechanistic insights into cellular processes such as intracellular trafficking, translation, and protein assembly. He has also contributed to the understanding of post translational gene regulation mechanisms through his study of iron metabolism. Furthermore, his investigations into the von Hippel-Lindau (VHL) protein have led to further classification of the protein’s tumor suppressive function in the context of renal cell carcinoma. His discovery of the T Cell Zeta chain and how T cells are activated was the basic science breakthrough that led to successful cell- based CAR-T cancer therapy. Throughout his career, Dr. Klausner has consistently worked to apply the principles of science and technology to address the global cancer burden.Dr. Klausner is well known for his work in cell and molecular biology, immunology and human genetics, and has been the author of more than 300 scientific articles and several books, in addition to receiving numerous awards, honorary degrees and other honors. He has served as an Advisor to the Presidents of the Academies for counterterrorism, and Liaison to the White House Office of Science &amp; Technology Policy. He oversaw the writing of The National Science Education Standards, the first such standards for US Science Education. He is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences.

Altos-Labs-Rick-Klausner

Rick Klausner

Chief Scientific Officer and Founder

Chief Scientist and Founder

Hans Bishop is President, Founder, and Board Co-Chairman of Altos Labs.&nbsp;He has more than 30 years of experience in the biotechnology industry.&nbsp;Bishop served previously as the CEO of GRAIL, which was recently acquired by Illumina.&nbsp;From 2013 to 2018, he served as President and CEO at Juno Therapeutics, a company that he co-founded and that was acquired by Celgene. Prior to Juno, Bishop served as an Executive in Residence at Warburg Pincus. Earlier in his career, he was the Executive Vice President and Chief Operating Officer for Dendreon. Bishop also previously served as President of Specialty Medicine at Bayer Healthcare and Senior Vice President of Global Commercial Operations at Chiron Corporation.&nbsp;He currently serves as the Chairman of Sana Biotechnology and as a Director of Lyell Immunopharma and Agilent Technologies.

Altos-Labs-Hans-Bishop

Hans Bishop

President and Founder

During life’s early stages cells display high levels of plasticity, regeneration and resilience against stress, disfunction and injury, which are key features of human health. Dr. Juan Carlos Izpisua Belmonte, previously the Roger Guillemin Chair and Professor at the Salk Institute, has contributed towards understanding the molecular basis underlying embryogenesis and early postnatal life, as well as gained insights into how to program and rejuvenate adult and diseased cells. He is developing technologies to program cells to states similar to those observed in the early, healthy stages of life, with the objective of developing universal health therapeutics to overcome human disease and aging.

Altos-Labs-Juan-Carlos-Izpisua-Belmonte

Juan Carlos Izpisua Belmonte

SVP and Director, San Diego Institute of Science

Founding Scientist and Director, San Diego Institute of Science

Kevin&nbsp;Sin is Chief Financial and Business Officer of Altos Labs. Kevin&nbsp;has nearly three decades of broad industry experience spanning business development, strategy, legal, and research and development.&nbsp;Prior to joining Altos, he served as the Senior Vice President and Head of Worldwide Business Development at GSK, where he was a member of the Research and Development Leadership Team and responsible for business development for all therapeutic areas, strategic technology platforms, global health, and externalization, as well as for global alliance management.Kevin previously served in multiple leadership roles at Genentech, including Vice President of Business Development.&nbsp;Prior to joining Genentech, he was a life sciences transactions attorney at Wilson Sonsini and worked in research at Bayer.&nbsp;He&nbsp;holds a BA in Molecular and Cell&nbsp;Biology&nbsp;from UC Berkeley and a JD from the University of San Francisco School of Law.

Altos-Labs-Kevin-Sin

Kevin Sin

Chief Financial and Business Officer

Dr. Wolf Reik is an MD and Director of the Altos Cambridge Institute of Science. He was previously Head of the Epigenetics Programme and subsequently Director of the Babraham Institute in Cambridge. He is also an honorary Professor of Epigenetics at the University of Cambridge. Dr. Reik’s lab works on epigenetic reprogramming in development and ageing. They discovered global epigenetic reprogramming and its mechanisms and impacts on mammalian development. Recently they developed new technologies for single cell multi-omics to understand cell fate decisions during development and how cell fate and function degrades during ageing. Applying epigenetic reprogramming to reset cell age they developed a protocol by which human cells can be substantially rejuvenated without loss of cell identity. Dr. Reik is a Fellow of the Royal Society.

Altos-Labs-Wolf-Reik

Wolf Reik

SVP and Director, Cambridge Institute of Science

Director, Cambridge Institute of Science

Dr. Peter Walter is Director of the Altos Bay Area Institute of Science and a Distinguished Professor in the Department of Biochemistry &amp; Biophysics at UCSF. He was a Howard Hughes Medical Institute Investigator until 2022. His laboratory has produced groundbreaking research related to the identification and characterization of key proteostasis networks including the Unfolded Protein and Integrated Stress Responses. In addition, Dr. Walter has the vision to leverage these observations into novel therapeutic interventions. His contributions to science have been recognized with many distinguished awards, including the 2014 Lasker Award and 2018 Breakthrough Prize. Dr. Walter has put together a select group of world-renowned experts in neuroscience, cell biology, molecular biology, microbiology, and RNA biology to make Altos Labs a reality.

Altos-Labs-Peter-Walter

Peter Walter

SVP and Director, Bay Area Institute of Science

Director, Bay Area Institute of Science

Dr. Hana El-Samad is Senior Vice President and Director of Science Integration, Innovation and Insights (S13) at Altos Labs, where she is also a Founding Principal Investigator.Prior to joining Altos Labs, Dr. El-Samad was the Kuo Family Endowed Professor in the Department of Biochemistry &amp; Biophysics and deputy-director of the Cell Design Institute at UCSF. She is a control and dynamical systems theorist whose work generated fundamental insights into the principles of precise and robust cellular responses through the use of feedback control. Her recent work pioneered real-time measurement of feedback in living cells, synthetic feedback technologies to program cellular function, and theoretical frameworks to quantify biological homeostasis. Dr. El-Samad is the recipient of many honors and awards including a 2011 Donald P. Eckman Award, 2013 Paul G. Allen Distinguished Investigator, 2017 senior investigator of the Chan-Zuckerberg Biohub and 2020 Fellow of the American Institute for Medical and Biological Engineering.

Altos-Labs-Hana-El-Samad

Hana El-Samad

SVP and Director, Science Integration, Innovation and Insights

Dr. Thore Graepel was previously Chair of Machine Learning at UCL, and has led research teams at Microsoft Research and DeepMind. He co-invented AlphaGo, the first computer program to defeat a human professional player in the game of Go. Major industrial applications of Dr. Graepel’s work include Xbox Live’s TrueSkill system and Bing’s AdPredictor system. His work on predicting personality traits from Facebook data served as an early warning sign about privacy concerns in social media. Dr. Graepel advocates for responsible innovation and served as a Board Member at the Partnership on AI. At Altos, he is building a world-class team in computational sciences, AI and ML to enable breakthroughs in cell health and rejuvenation.

Altos-Labs-Thore-Graepel

Thore Graepel

SVP, Computational Science, Artificial Intelligence, and Machine Learning

SVP and Head, Computational Science, Artificial Intelligence, and Machine Learning

Dr. Laurie Hill is the General Counsel and Chief Compliance Officer of Altos Labs.&nbsp;She is an architect of pragmatic solutions that foster bold innovation, a builder of diverse high performing teams anchored in courage, creativity, and curiosity, and a catalyst for growth that delivers results. Dr. Hill is a bold yet pragmatic visionary for possibilities in a 4th industrial revolution fusing physical, digital, and biological spheres to sustainably grow economies and improve lives. She has led successful global IP teams at Genentech, Illumina, MedImmune, and Life Technologies. Dr. Hill holds a J.D. from the University of Texas School of Law and a Ph.D. in Microbiology and Immunology from Thomas Jefferson University. She was recognized as Luminary Leader by the Healthcare Businesswomen’s Association in 2020.

Altos-Labs-Laurie-Hill

Laurie Hill

General Counsel

General Counsel and Chief Compliance Officer

Connie White started at Altos Labs in September 2021, and is committed to leading a People organization that is innovative and creates an amazing employee experience. White is a certified Professional Coach, and has deep experience in developing and facilitating senior leadership development programs, creating enterprise career and talent acquisition strategies,&nbsp;and establishing university relationships.&nbsp;Prior to joining Altos Labs, White worked at Genentech in the Human Resources and the U.S. Commercial functions. In past roles, She has served on senior diversity &amp; inclusion steering committees, and has led operations and communications functions across complex organizations.&nbsp;White graduated from University at Albany with a B.A. in Asian Studies and History.

Altos-Labs-Connie-White

Connie White

VP, People

Danielle Morris is Vice President of Strategic Partnerships at Altos Labs. She leads Communications, works closely with Business Development and supports effective decision making, project management and the execution of strategic initiatives for the Executive Committee and the CEO.&nbsp;Prior to joining Altos in December 2022, Danielle was the Chief of Staff for R&amp;D and Portfolio Investment at GSK. She was responsible for driving the effectiveness of the R&amp;D organization, including allocation of capital across the development pipeline.&nbsp;Danielle brings a decade of global experience across communications, finance, commercial and R&amp;D. She holds a BA in Politics from the University of York, UK and is a certified management accountant.&nbsp; &nbsp;

Altos-Labs-Danielle-Morris

Danielle Morris

VP, Strategic Partnerships

Leadership

Dr. Shinya Yamanaka serves as senior scientific advisor to Altos Labs without remuneration, overseeing research activities in Japan. Dr. Yamanaka is a Senior Investigator and the L.K. Whittier Foundation Investigator in Stem Cell Biology at the Gladstone Institute for Cardiovascular Disease. He is also a Professor of Anatomy at the University of California, San Francisco, as well as a Director and Professor of the Center for iPS Cell Research and Application (CiRA) at Kyoto University. Dr. Yamanaka earned an MD from Kobe University and a PhD from Osaka City University. He became an Assistant Professor at Osaka City University Medical School, and later an Associate Professor at Nara Institute of Science and Technology, where he eventually became a full Professor in 2003. Dr. Yamanaka attained professor position at Kyoto University in 2004, and was appointed Senior Investigator at Gladstone Institutes in 2007. Since 2008, he has been directing CiRA.&nbsp;In 2012, Dr. Yamanaka was awarded the Nobel Prize in Physiology or Medicine for his discovery that adult somatic cells can be reprogrammed into pluripotent cells. In addition, he has received many awards and honors, including the Albert Lasker Basic Medical Research Award, the Wolf Prize in Medicine, the Millennium Technology Award, the Shaw Prize, the Kyoto Prize for Advanced Technology, the Gairdner International Award, the Robert Koch Award.

Altos-Labs-Shinya-Yamanaka

Shinya Yamanaka

Japan Senior Scientific Advisor

Senior Scientific Advisor

Scientific Advisor

Dr. Frances Arnold is the Linus Pauling Professor of Chemical Engineering, Bioengineering and Biochemistry at the California Institute of Technology. Dr. Arnold received the Nobel Prize in Chemistry (2018) for pioneering directed evolution methods used to make enzymes for applications across medicine, consumer products, agriculture, fuels and chemicals. She was appointed Co-Chair of the Presidential Council of Advisors for Science and Technology (PCAST) by President Biden in 2021.Co-inventor on more than 60 issued US patents and active in technology transfer, Dr. Arnold co-founded Gevo, Inc. in 2005 to make fuels and chemicals from renewable resources, Provivi, Inc. in 2014 to develop non-toxic modes of agricultural pest control, and Aralez, Inc. in 2019 to develop sustainable biocatalytic processes for producing medicines and chemicals. She is a Director of Illumina and Alphabet and also serves on the Advisory Panel of the David and Lucile Packard Foundation Fellowships in Science and Engineering and as a Trustee of the Gordon Research Conferences. Dr. Arnold has been elected to the American Academy of Arts and Sciences, the American Philosophical Society, and the US National Academies of Science, Medicine, and Engineering; she was appointed to the Pontifical Academy of Sciences by Pope Francis in 2019. She received her B.S. in Mechanical and Aerospace Engineering from Princeton University and her Ph.D. in Chemical Engineering from the University of California, Berkeley.

Altos-Labs-Frances-Arnold

Frances Arnold

Director

Dr. David Baltimore served as President of the California Institute of Technology from 1997 until 2006. He is currently President Emeritus and Judge Shirley Hufstedler Professor of Biology at Caltech. Awarded the Nobel Prize in 1975 for research in virology, Dr. Baltimore has profoundly influenced national science policy on such issues as recombinant DNA research and the AIDS epidemic. He is an accomplished researcher, educator, administrator and public advocate for science and engineering and is considered one of the world’s most influential biologists.For almost 30 years, Dr. Baltimore was a faculty member at Massachusetts Institute of Technology. He served as founding director of the Whitehead Institute for Biomedical Research at MIT from 1982 until 1990. An early advocate of federal AIDS research, he co-chaired the 1986 National Academy of Sciences committee on a National Strategy for AIDS and was appointed in 1996 to head the National Institutes of Health AIDS Vaccine Research Committee. Dr. Baltimore served as a member of the Independent Citizen’s Oversight Committee to the California Institute for Regenerative Medicine until 2007 and on the Board of Directors for MedImmune until 2007, Cellerant until 2008, Calimmune until 2017, Amgen until 2018 and Immune Design until 2019.He has played an important role in the development of American biotechnology since his involvement in the 1970’s in the formation of Collaborative Genetics. Dr. Baltimore helped found Calimmune and Immune Design and he presently serves on the Board of Directors at several companies and non-profit institutions including Appia Bio, the Broad Institute, and Regulus Therapeutics. He is a member of numerous Scientific Advisory Boards, including the Broad Institute, PACT Pharma, Ragon Institute, Regulus Therapeutics, Vir Biotechnology and Volastra Therapeutics. He is a Scientific Partner to the venture capital firm, The Column Group, and was a Director of the Swiss investment company BB Biotech through 2011.Dr. Baltimore’s numerous honors include the 1999 National Medal of Science, 2000 Warren Alpert Foundation Prize, and 2021 Lasker~Koshland Special Achievement Award in Medical Science. He was elected to the National Academy of Sciences in 1974 and is also a fellow of the American Academy of Arts and Sciences, and a foreign member of both the Royal Society of London and the French Academy of Sciences. He is past-President and Chair of the American Association of the Advancement of Science (2007-2009) and was named a Fellow of the American Association for Cancer Research (AACR). He has published more than 700 peer-reviewed articles.

Altos-Labs-David-Baltimore

David Baltimore

Lead Independent Director

Dr. Jennifer Doudna, biochemist and Nobel Prize winning co-inventor of CRISPR technology. Dr. Doudna is a biochemist at the University of California, Berkeley. Her groundbreaking development of CRISPR-Cas9 — a genome engineering technology that allows researchers to edit DNA — with collaborator Emmanuelle Charpentier earned the two the 2020 Nobel Prize in Chemistry and forever changed the course of human and agricultural genomics research. She is also the Founder and President of the Innovative Genomics Institute, the Li Ka Shing chancellor’s chair in Biomedical and Health Sciences, and a member of the Howard Hughes Medical Institute, Lawrence Berkeley National Lab, Gladstone Institutes, the National Academy of Sciences, and the American Academy of Arts and Sciences. Dr. Doudna is a leader in the global public debate on the responsible use of CRISPR and has co-founded and serves on the advisory panel of several companies that use the technology in unique ways. She is the co-author of “A Crack in Creation,” a personal account of her research and the societal and ethical implications of gene editing.

Altos-Labs-Jennifer-Doudna

Jennifer Doudna

Karl Johansson is an advisor and consultant for multi-national companies with a focus on technology, financial institutions, and energy. He currently serves as a board member or on management committee for the Breakthrough Prize Foundation, Analytical Credit Rating Agency (ACRA) (Moscow), the China- Russia Eurasia Studies Center (CREC), and the Institute for Emerging Markets Studies&nbsp;at the&nbsp;Skolkovo School Management in Moscow.Johansson brings a passion for innovation in the technology and biotechnology arenas. He retired as Managing Partner from Ernst &amp; Young where he served international and domestic clients on tax, venture capital, multinational company acquisitions, capital markets, restructuring, and executive compensation. He has served on World Economic Forum committees and on the executive committee and board of the America Chamber of Commerce Russia. With that, Johansson brings deep financial expertise and extensive international experience to emerging and growing companies.Johansson holds a Juris Doctorate from University of Pennsylvania and a Bachelor of Art in American Studies from University of Minnesota.

Altos-Labs-Karl-Johansson

Karl Johansson

Dr. Maria Leptin is the President of the ERC. Her research groups at the EMBL in Heidelberg and the University of Cologne study the biophysics of cell shape changes. After receiving her PhD at the Basel Institute for Immunology, Switzerland, Dr. Leptin moved to the LMB in Cambridge, UK, became a group leader at the Max-Planck-Institute in Tübingen and then professor at the Institute of Genetics, Cologne. She spent time on sabbaticals or as visiting professor at UCSF, the École normale supérieure in Paris, and the Wellcome Trust Sanger Institute at Hinxton. From 2010 to 2021, Dr. Leptin was the Director of EMBO. She is an elected member of EMBO, the Academia Europaea, the German National Academy, Leopoldina, an Honorary Fellow of the UK Academy of Medical Sciences, and holds an Honorary Doctorate from the EPFL, Lausanne.

Altos-Labs-Maria-Leptin

Maria Leptin

Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners.&nbsp;He joined ARCH at its founding and played a significant role in the creation, early sourcing, financing and development of more than 150 companies, including 38 which have reached valuations exceeding $1 billion.Nelsen is focused on generating new ideas for disruptive technologies or business models and partnering with founding management teams and entrepreneurs to execute on these visions by advancing novel platform technologies with the overarching goal of improving health care and outcomes.Some of his notable early-stage investments include&nbsp;Illumina, Alnylam Pharmaceuticals, Juno Therapeutics (acquired by Celgene), Beam Therapeutics, Karuna Therapeutics, Altos Labs, EQRx, Lyell Immunopharma, Array BioPharma (acquired by Pfizer), Unity Biotechnology, Hua Medicine, Vir Biotechnology, Agios Pharmaceuticals, Sage Therapeutics, GRAIL (acquired by Illumina), Gossamer Bio, Ikaria (acquired by Mallinckrodt), Kythera Biopharmaceuticals (acquired by Allergan), Receptos (acquired by Celgene), Aviron (acquired by MedImmune), Denali Therapeutics, Rubius Therapeutics, Syros Pharmaceuticals, Sana Biotechnology, Verve Therapeutics, Brii Biosciences, Bluebird Bio, R2 Technology (acquired by Hologic), Caliper Life Sciences (acquired by PerkinElmer), Trubion Pharmaceuticals (acquired by Emergent Biosolutions), Adolor (acquired by Cubist), deCODE Genetics (acquired by Amgen), Editas, 10x Genomics, Semma Therapeutics (acquired by Vertex), and IDUN Pharmaceuticals (acquired by Pfizer).Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.

Altos-Labs-Robert-Nelsen

Robert Nelsen

Dr. Raj Shah is president of the Rockefeller Foundation, a global institution committed to promoting the well-being of humanity around the world through data, science and innovation. Under his leadership, the foundation raised and deployed more than $1 billion to respond to the COVID pandemic at home and abroad, launched a Pandemic Prevention Institute to prevent future health crises, and created a $10 billion Global Energy Alliance for People and Planet to help secure a just and green recovery. Dr. Shah serves on President Biden’s Defense Policy Board and is a member of the American Academy of Arts and Sciences and the Council on Foreign Relations.Previously, Dr. Shah was the 16th Administrator of the U.S. Agency for International Development where he reshaped the $20 billion agency’s global operations and secured bipartisan support for America’s leading development and humanitarian role in the world. He led the U.S. response to the 2010 Haiti earthquake and Pakistani floods, 2011 East African famine and the 2014 Ebola pandemic. For his efforts in support of U.S. national security and foreign policy, he was awarded the U.S. Global Leadership Award. Dr. Shah previously served as Chief Scientist and Undersecretary for Research, Education and Economics at the Department of Agriculture where he created the National Institute for Food and Agriculture. In both roles, Dr. Shah was appointed by President Obama and unanimously confirmed by the U.S. Senate.Dr. Shah also founded Latitude Capital, served on the United Nations High Level Panel on Pandemics, and taught as a&nbsp;Distinguished Fellow in Residence at Georgetown University. Previously, he served at the Bill &amp; Melinda Gates Foundation, where he created the International Financing Facility for Immunization which helped reshape the global vaccine industry and save millions of lives.&nbsp;Dr. Shah is a graduate of the University of Michigan, the University of Pennsylvania School of Medicine, and the Wharton School of Business.&nbsp;He has received numerous honorary degrees, the Thomas Jefferson Medal from the University of Virginia, and the Secretary of State’s Distinguished Service Award.&nbsp;

Altos-Labs-Rajiv-Shah

Rajiv Shah

Board of Directors

Dr. Acosta-Alvear is a Principal Investigator at the Altos Labs Bay Area Institute of Science. Prior to joining Altos, he was an Assistant Professor in the Department of Molecular, Cellular, and Developmental Biology at University of California, Santa Barbara. He has made several contributions to our understanding of the ISR and UPR signaling mechanisms. In his graduate work at NYU, Dr. Acosta-Alvear discovered how the UPR controls cellular developmental decisions, and as a postdoc in the laboratory of Peter Walter, he discovered conserved stress-sensing principles of the UPR stress sensor IRE1 and its interconnectivity with the cell's protein synthesis machinery. Dr. Acosta-Alvear is also a co-discoverer of the small-molecule ISR inhibitor ISRIB and has collaborations with the groups of Costa-Mattioli and Walter on protein homeostasis. His group at UCSB recently discovered new signaling principles and layers of interconnectivity between the ISR and the UPR.

Altos-Labs-Diego-Acosta-Alvear

Diego Acosta-Alvear

Dr. Simone Bianco is a Principal Investigator at the Altos Labs Bay Area Institute of Science. Prior to joining Altos he was a research staff member and manager of the department of Functional Genomics and Cellular Engineering at the IBM Almaden Research Center. He is an expert in computer driven design of biological systems. Dr. Bianco has contributed to the design of vaccines, antivirals, antimicrobials and immunotherapies, and holds several patents in synthetic biology. He is founding PI of the NSF Center for Cellular Construction, which aims at transforming cell biology into an engineering discipline. Dr. Bianco is a TED speaker with over 1M views, recipient of IBM’s Outstanding Research Achievement Award, and an honorary visiting lecturer for the Society for Industrial and Applied Mathematics, for his standing in the field of dynamical systems and commitment to education.

Altos-Labs-Simone-Bianco

Simone Bianco

Prior to joining Altos Labs, Dr. Jin Chen was an Assistant Professor at the University of Texas Southwestern Medical Center. Dr. Chen is one of the leaders in the emerging field of the “microproteome”. He uncovered pervasive non-canonical translation of the mammalian genome, encoding a whole universe of novel, unannotated proteins. In addition, he developed various CRISPR-based tools and functional genomic techniques. His lab is interested in building innovative tools to explore the organizational principles of the genome and transcriptome, as well as studying the information encoded in the genome and how the expression of this information is regulated during cellular stress and aging. Before UT Southwestern, he did his postdoctoral research with Jonathan Weissman at the University of California San Francisco and received his Ph.D. from Stanford University with Jody Puglisi. He has received numerous awards for his work, including a NIH Pathway to Independence Award, Endowed Scholar award from UT Southwestern, CPRIT Award, Searle Scholar Award (declined), and the NIH Director’s New Innovator Award (declined).

Altos-Labs-Jin-Chen

Jin Chen

Dr. Mauro Costa-Mattioli is a Principal Investigator at the Altos Labs Bay Area Institute of Science and an adjunct Professor in the Department of Neuroscience, Cullen Foundation Endowed Chair in Neuroscience &amp; Director of the Memory &amp; Brain Research Center at Baylor College of Medicine. Dr Costa-Mattioli has elucidated central mechanisms underlying neurological dysfunction. Specifically, he discovered that the protein homeostasis network dubbed the integrated stress response (ISR) is a universal regulator of long-term memory formation, and its activation the main causative mechanism underlying cognitive dysfunction in a wide range of memory disorders. Dr. Costa-Mattioli discovered and characterized the mechanism(s) by which specific microbes in the gut modulate brain function and complex behaviors. His awards include the International Eppendorf &amp; Science Prize in Neurobiology, the Searle Scholar Award, the International Society for Neurochemistry Young Investigator Award, and the UCSF Presidential Award.

Altos-Labs-Mauro-Costa-Mattioli

Mauro Costa-Mattioli

Dr. Ebru Erbay is a Principal Investigator at the Altos Labs Bay Area Institute of Science.Prior to joining Altos, she was an Associate Professor in the Departments of Cardiology and Biomedical Sciences at Cedars-Sinai Medical Center and David Geffen School of Medicine at UCLA. Dr. Erbay was an Assistant Professor in the Department of Molecular Biology and Genetics in Bilkent University. She studies organelle stress at the epicenter of immunometabolism. Dr.Erbay demonstrated the causality of endoplasmic reticulum stress for atherosclerosis while illuminating the therapeutic potential of modulating this stress response in cardiovascular disease.She discovered a bioactive lipid that can remodel organelle membranes, rendering them resilient to hyperlipidemia-induced damage. Dr. Erbay's current work focuses on a hyperlipidemia-induced immunometabolite that can becounteracted to prevent atherosclerosis.She received the Sabri Ulker Science Award in 2017.

Altos-Labs-Ebru-Erbay

Ebru Erbay

Dr. Adam Frost is a Principal Investigator at the Altos Labs Bay Area Institute of Science. Prior to joining Altos, he was an Associate Professor and the Herbert Boyer Junior faculty endowed chair in the Department of Biochemistry and Biophysics at the University of California, San Francisco, a Chan Zuckerburg Investigator, and a HHMI faculty scholar. The Frost laboratory studies the behavior of molecular networks that govern homeostasis. By integrating atomic-scale structure determination by cryo-EM with genetics, biochemistry, and other imaging techniques, the Frost lab determined central mechanisms governing the shapes and connectivities of cellular organelles. The Frost lab also contributes to our understanding of how cells regulate protein synthesis levels in response to cellular stress, from translation initiation control to the detection and degradation of problematic nascent proteins. Dr. Frost's awards include the NIH Director's New Innovator Award and the Searle Scholars Award.

Altos-Labs-Adam-Frost

Adam Frost

Dr. Jodi Nunnari is a Principal Investigator at the Altos Labs Bay Area Institute of Science. Prior to joining Altos, she was a Distinguished Professor in the Department of Molecular and Cellular Biology at the University of California, Davis. Dr. Nunnari is a pioneer in the mitochondrial biology field. She was the first to describe mitochondria as a dynamic network in homeostatic balance and her lab described the mitochondrial division and fusion machines. Her lab has uncovered additional mechanisms underlying mitochondrial behavior, including how mitochondrial membranes are organized, how mitochondria communicate with the endoplasmic reticulum, and how the mitochondrial genome is transmitted. Dr. Nunnari is an elected member of the National Academy of Sciences, the European Molecular Biology Organization and the American Academy of Arts and Sciences.

Altos-Labs-Jodi-Nunnari

Jodi Nunnari

Dr. Susanna Rosi is a Principal Investigator at the Altos Labs Bay Area Institute of Science. Prior to joining Altos, she was the Lewis and Ruth Cozen Chair II, Professor in the Departments of Physical Therapy Rehabilitation Science and Neurological Surgery at UCSF. Dr. Rosi studies the mechanisms responsible for the cognitive dysfunctions observed after traumatic brain injury, therapeutic brain irradiation and galactic cosmic ray exposure. Her work provided the mechanistic evidence for the role of microglia in the development of cognitive deficits after brain injury based on sex. She was the first to demonstrate that modulation of the Integrated Stress Response rescues cognitive deficits after brain trauma; rejuvenates old mice by alleviating memory deficits and restoring neuronal and immune dysfunction. Dr. Rosi has been the recipient of several NCI, NIA, NINDS awards and she is a NASA investigator. Most recently she received the 2021 J.W. Osborne Award.

Altos-Labs-Susanna-Rosi

Susanna Rosi

Institutes of Science

Dr. Steve Horvath is a Principal Investigator at the Altos Labs San Diego Institute of Science. Prior to joining Altos, he was a Professor of Human Genetics and Biostatistics at the University of California, Los Angeles. His research lies at the intersection of several fields including biogerontology, anti-aging clinical trials, epigenetic biomarkers of aging, epidemiology, systems biology, and comparative biology. Dr. Horvath and his UCLA colleagues published the first epigenetic clock for saliva in 2011, the first pan-tissue clock (2013), and the first pan mammalian clock (2021). He is also known for developing weighted correlation network analysis (WGCNA), a widely used data mining method used in genomic applications. The recipient of several awards, Dr. Horvath has been on Clarivate’s annual list of the world’s most influential scientific researchers every year since 2018.

Altos-Labs-Steven-Horvath

Steve Horvath

Dr. Peter Kharchenko is a Principal Investigator at the Altos Labs San Diego Institute of Science. Prior to joining Altos, he was a Gilbert S. Ommen Associate Professor of Biomedical Informatics at Harvard Medical School. His group has developed key methods for genomic analysis of single cells, enabling statistical separation of distinct cellular states, detection of genomic aberrations in transcriptional data, and inference of cellular dynamics from snapshots of cellular state. His group has also applied these approaches to study the organization of different tissues and the impact of diseases ranging from cancer to schizophrenia. At Altos, Peter’s group will study how cells coordinate their activity within complex biological tissues, how these mechanisms break down in the context of aging or disease, and investigate the potential interventions that may improve tissue function. Much of the effort will be focused on development and application of novel statistical methods and computational tools for understanding tissue function, including analysis of multi-omics and spatial assays.

Altos-Labs-Peter-Kharchenko

Peter Kharchenko

Dr. Morgan Levine is a Principal Investigator at the Altos Labs San Diego Institute of Science. Prior to joining Altos, she was a ladder rank professor in the department of Pathology at Yale University School of Medicine. Levine is considered a leader in the biology of aging, most famous for generating cutting-edge methods for quantifying the system dysregulation that occurs over an organisms' lifetime. Her work relies on interdisciplinary approaches, integrating theories and techniques from bioinformatics and cellular and molecular biology to track trajectories aging cells and organisms take over time.&nbsp;Her vision is to link molecular changes in aging, development, and reprogramming to dynamical features of cells and to uncover how these alterations impact homeostasis at the tissue or organ-system level. Dr. Levine has received numerous awards for her work, including the Vincent Cristofalo Rising Star Award in Aging Research in 2021 and the Nathan Shock New Investigator Award in 2020.

Altos-Labs-Morgan-Levine

Morgan Levine

Dr. Zachary Levine is a Principal Investigator at the Altos Labs San Diego Institute of Science. Prior to joining Altos, he was an Assistant Professor of Pathology and Molecular Biophysics &amp; Biochemistry at the Yale School of Medicine. His research interests focus on using biophysical techniques to better understand the roles of promiscuous protein assemblies in aging that evade degradation. The Levine Lab seeks to measure the heterogeneity of individual protein complexes through a combination of molecular modeling, single-molecule fluorescence, and small-molecule interventions in cells and tissues. These integrated techniques highlight the shared molecular determinants of age-related disorders and cellular senescence, leading to a mechanistic description of biological aging that is sensitive to aberrant protein aggregation. Dr. Levine is currently a Fellow of Branford Residential College, a Yale Pepper Center Scholar, a council member for the Biophysical Society’s Intrinsically Disordered Protein Subgroup, and has received numerous NIH/NIA training and research grants.

Altos-Labs-Zachary-Levine

Zachary Levine

Dr. Kun Zhang is a Principal Investigator at the Altos Labs San Diego Institute of Science. Prior to joining Altos, he was the Leo and Trude Szilard Chair Professor and Chairman of the Bioengineering Department at University of California, San Diego. His area of expertise is molecular engineering and biotechnology, with a specialization on genomics, epigenomics and single-cell sequencing. Dr. Zhang pioneered the development of methods on target genome and epigenome sequencing, single cell genome sequencing, single-nucleus RNA sequencing, and single-cell multi-omics sequencing. He is applying these technologies to constructing single-cell atlases for major human organs. Dr. Zhang has been a Web of Science highly cited researcher since 2019, and was elected Fellow of the American Institute for Medical and Biological Engineering in 2017 and of the International Academy of Medical and Biological Engineering in 2021.

Altos-Labs-Kun-Zhang

Kun Zhang

Investor

Dr. Pura Muñoz-Cánoves is a principal investigator at the Altos Labs San Diego Institute of Science. Prior to joining Altos, she was an ICREA Professor and Cell Biology Professor at the Pompeu Fabra University in Barcelona, and Senior Scientist at the Spanish National Cardiovascular Research Center in Madrid, Spain. Her discoveries have set new paradigms on how stem cells age. For instance, her lab was the first to demonstrate that at advanced (geriatric) age, quiescent muscle stem cells undergo proteostatic failure, leading to senescence, a reprogramming of their normal daily circadian functions, and eventually, to regenerative impairment. These findings have already changed the classical conception of dormancy for adult stem cells and their regenerative functions, and have ample implications in regenerative medicine and aging. Her awards include the 2015 Pfizer and 2019 Lilly prizes in biomedicine, the 2019 King Jaume I Prize, and 2021 Spain National Prize Santiago Ramón y Cajal in Biomedicine, as well as ERC awards and permanent membership in EMBO and Academia Europaea.

Altos-Labs-Pura-Munoz-Canoves

Pura Muñoz-Cánoves

Dr. Maria Abad studies the interplay between stress responses and cellular plasticity. She discovered that cellular reprogramming is feasible in living organisms, and has contributed to the demonstration that tissue damage, through the induction of cellular senescence, creates a microenvironment critical for cellular reprogramming. More recently, Dr. Abad has studied the translation of small open reading frames (sORFs) located in assumed non-coding regions, and her group has identified several lncRNA-derived small proteins with important roles in cellular plasticity. At Altos Cambridge, she will aim to create a multidisciplinary and collaborative program to unravel how the proteome is shaped to cope with stress, and to identify novel cell-intrinsic and cell-extrinsic determinants of cellular reprograming and tissue rejuvenation.

Altos-Labs-Maria-Abad

Maria Abad

Kevin Chalut is a physical biologist with a PhD in Physics from Duke University. Prior to joining Altos Labs, he was a group leader at the Wellcome Trust-MRC Cambridge Stem Cell Institute at the University of Cambridge. During his time there, his lab performed seminal work understanding how the mechanical environment and mechanical properties of cells affect stem cell fate choices across the lifespan, and how the mechanical environment can lead to loss of function in stem cells. His work focuses on using the tools and concepts of physics to study cell fate choice and regeneration both in cells and tissues. He primarily investigates how external and internal mechanical inputs regulate fate decisions, and exactly how cells process information during that fate choice. His ultimate goal is to apply physics-based techniques to understand how organisms develop and maintain tissues, and how to use stem cells for therapeutic use in extending healthy lifespan. His primary objective is to bring together physics, engineering and biology to better understand cell fate choices, and how to control stem cells to enhance tissue function.

Altos-Labs-Kevin-Chalut

Kevin Chalut

Dr. Martin Denzel is a Principal Investigator at the Altos Labs Cambridge Institute of Science. Prior to joining Altos, he was a research group leader at the Max Planck Institute for Biology of Ageing in Cologne, Germany. He studies the molecular underpinnings of longevity using high-resolution genetic screens in multiple organisms, including worms and mice. Dr. Denzel investigates energy and protein metabolism as well as conserved stress signaling pathways that can be tuned to extend survival. To elucidate underlying molecular mechanisms Dr. Denzel employs structural biology approaches. Recently, his team showed that inhibition of the integrated stress response (ISR) extends lifespan. For his basic research, Dr. Denzel received support from all major European and German funding organizations, including EMBO and ERC. He aims to apply basic research and co-founded the start-up company Acus Laboratories.

Altos-Labs-Martin-Denzel

Martin Denzel

Associate Principal Investigator

Dr. Robin Franklin was previously Professor of Stem Cell Medicine at the Wellcome-MRC Cambridge Stem Cell Institute at the University of Cambridge. His laboratory has made many pioneering discoveries on the mechanisms by which adult CNS progenitors replace lost oligodendrocytes, describing how their function declines with aging and how this can be reversed, by, for example, partial reprogramming and manipulation of physical properties of the niche. Dr. Franklin’s laboratory will develop multidisciplinary collaborative links to further explore the underlying mechanisms of adult somatic stem cell aging. He is a Fellow of both the Academy of Medical Sciences and the Royal Society, as well as the recipient of the 2017 Barancik International Prize for Research Innovation and the 2021 King Faisal Prize for Medicine.

Altos-Labs-Robin-Franklin

Robin Franklin

Dr. Giovanna Mallucci is a Principal Investigator at the Altos Labs Cambridge Institute of Science. She was previously van Geest Professor of Clinical Neurosciences and Center Director of the UK Dementia Research Institute at the University of Cambridge. Following her discovery of the reversibility of early neurodegeneration, her lab pioneered the understanding of the role of the Unfolded Protein Response (UPR) in neurodegenerative diseases and its therapeutic manipulation for neuroprotection, including discovering repurposable drugs ready for clinical trials. Dr. Mallucci’s interest in neuroprotection led to the discovery of ‘hibernation’ proteins in synapse regeneration that can be targeted therapeutically. She is Fellow of the Academy of Medical Sciences and received the 2021 Potamkin Prize for Research in Pick’s, Alzheimer’s and Related Disorders. Dr. Mallucci is a practicing neurologist, specialized in dementia.

Altos-Labs-Giovanna-Mallucci

Giovanna Mallucci

Dr. Ken Raj joins Altos from Public Health England. He will investigate the mechanisms that underpin epigenetic changes that accompany ageing. By employing human cell ageing assays he developed based on epigenetic clocks, Dr. Raj will elucidate the common denominators that link the different hallmarks of ageing. He will also explore how distinct cell populations in tissues alter in function of age. The human cell ageing assays will be leveraged to identify interventions that perturb epigenetic clocks and ageing, with the view of understanding the clock at the molecular level. Together with Steve Horvath, he will bring mouse epigenetic clocks to bear on large-scale genetic screen of mutant mice to elucidate genes associated with epigenetic ageing.

Altos-Labs-Ken-Raj

Ken Raj

Dr. Manuel Serrano joins Altos Cambridge from the Institute for Research in Biomedicine (IRB), Barcelona, Spain. He has been working on cellular senescence for almost 30 years since his discovery of the master senescence gene p16 and the phenomenon of oncogene-induced senescence. Dr. Serrano combines work on senescence with cellular reprogramming. His group was the first to report that reprogramming can be achieved within tissues in intact organisms and this is strongly promoted by tissue damage signals. Dr. Serrano’s team is currently focused on the identification of intermediate reversible states of reprogramming and their relevance for tissue rejuvenation. The overarching goal of his research is to find pharmacological and dietary interventions that mimic intermediate reprogramming and trigger rejuvenation.

Altos-Labs-Manuel-Serrano

Manuel Serrano

Dr. Dolo Diaz is Senior Vice President and Head of Development Sciences at Altos Labs. Dr. Diaz is a translational scientist and drug developer with 20+ years of drug discovery, development, regulatory, team leadership, and organizational leadership experience.Prior to joining Altos, Dr. Diaz was the Senior Vice President of Development Sciences at Denali Therapeutics, where she built and led a translational organization that included Omics, DMPK, Bioanalysis, Clinical/Quantitative Pharmacology, and Safety Assessment; led project teams for small molecules and biotherapeutic programs, and had roles in portfolio leadership and oversight, corporate goal setting, and long-range planning. Dr. Diaz previously was Head of Discovery Toxicology at Genentech, where she built and led a team in charge of discovery safety strategies for small molecules across therapeutic areas, and had roles in portfolio entry and progression. Before that, Dr. Diaz built and led the In-vitro Toxicology group at Eurofins.Dr. Diaz received her PhD in Toxicology from the University of Washington, followed by post-doctoral work at the Fred Hutchinson Cancer Research Center in Seattle.

Dolo Diaz.png

Dolo Diaz

Dr. Nancy Krieger, MD, is Global Head and SVP of Early Clinical Development of Altos Lab. She was previously Chief Medical Officer of Talaris Therapeutics, responsible for development activities investigating a novel allogeneic cell therapy to induce tolerance in organ transplantation and auto-immune disease. Prior to joining Talaris, she was Senior Global Program Clinical Head at Novartis. She has 20 years of global drug development experience spanning cellular therapy, biologics and small molecules, in diverse therapeutic areas including solid organ and stem cell transplantation, immunology/inflammation, rare disease, bone metabolism and chronic kidney and liver disease. Before industry, Dr. Krieger was a staff transplant surgeon at Mount Sinai School of Medicine in New York, where she had an active practice in adult and pediatric liver transplantation as well as a basic science laboratory investigating lymphocyte trafficking in transplant tolerance. She completed her transplant fellowship at the University of Wisconsin, and general surgical residency at Stanford University, including a 3-year postdoctoral fellowship in Stanford’s immunology department. Nancy earned her MD at Columbia University College of Physicians and Surgeons.

Nancy Krieger_web.png

Nancy Krieger

Dr. Sharon Wang is Global Head and Senior Vice President of Technical Operations at Altos Labs. She has 30 years of drug development experience in the biotech industry. Dr. Wang has filed over 40 INDs for new molecular entities and 10+ BLAs/NDAs. She has deep expertise in technical operations and extensive experience leading broad drug development programs.Prior to joining Altos, Dr. Wang served as the Senior Vice President of Technical Development at Ultragenyx Pharmaceuticals. She built an outstanding Technical Development organization from scratch covering 10 development programs across multiple modalities including mRNAs, ASOs, proteins, antibodies, and small molecules. Prior to this, Dr. Wang has served in increasing capacities at Biogen, Genentech and Abbvie.Dr. Wang holds a PhD in Biophysical Chemistry, a MS in Biochemistry, and a BS in Chemistry.

Sharon Wang.jpg

Sharon Wang

Institute of Medicine

David Williamson is the Senior Vice President of Finance and Procurement for Altos. He brings 25 years of finance experience in Corporate Planning, Business Development, and Business Operations, with 15 years of Research and Development finance experience in the Life Sciences industry. Most recently Williamson served as the Vice President of Global Product Development finance at Roche. Previously he was the Head of Finance for the Genentech Research and Early Development organization, overseeing all finance operations, planning and business development finance activities. Earlier in his career, Williamson spent 8 years in retail finance at Gap Inc. in various Corporate Planning and Real Estate strategy roles. He holds a B.S. in Accounting and Entrepreneurship from the University of St. Thomas.

Altos-Labs-David-Williamson

David Williamson

SVP, Finance

SVP, Finance and Procurement

Nimit Arora joined Altos as VP of Finance and Accounting in January 2022 and brings 20 years of finance, accounting, and operations experience with global companies in the Life Sciences and Biotechnology sector. Prior to joining Altos Labs, he served as Corporate Controller at Atara Biotherapeutics from May 2017 to December 2021, helping build and scale the finance organization for a growing public company. Before Atara, he worked at PricewaterhouseCoopers for 11 years serving clients in both public and private sectors in the Life Science and Venture Capital audit practice in the firm’s San Jose Office. Earlier in his career, Arora worked at Grant Thornton India and KPMG India serving clients in both public and private sectors.&nbsp;He holds a Bachelor’s in Commerce from Delhi University, India and is a Certified Public Accountant licensed in California and Chartered Accountant from India.

Altos-Labs-Nimit-Arora

Nimit Arora 

VP, Finance and Accounting

Dr. Travis Berggren joined Altos Labs from the Salk Institute of Biological Studies, where he was Executive Director of Research Operations, providing executive oversight of shared scientific resources. He brings decades of experience to Altos in establishing and running a diverse portfolio of scientific cores and shared research resources. Early in his career, Dr. Berggren worked on DNA sequencing technology development and mass spectrometry-based proteomics. He has been active in human stem cell research for nearly 20 years, and has overseen the establishment and renovation of more than a dozen scientific cores that range from imaging, and flow cytometry to those involving multiomics, like NGS, bioinformatics, proteomics and single cell analysis.

Altos-Labs-Travis-Berggren

Travis Berggren

VP, Scientific Operations

Cheri Curry is a procurement and operations leader. For over two decades, she has served in global biotechnology and pharmaceutical organizations, and in the MENA region at a state-of-the-art international biomedical research center, during various stages of organizational development, including startups, large R&amp;D and manufacturing operational activities, and mergers &amp; acquisitions. Curry supports scientists to devise sustainable procurement strategies, systems optimizations, maintain strategic relationships, and provide expert negotiation skills. She co-led a COVID task force to protect critical workforce during the pandemic at GRAIL. Curry currently serves on BIOCOM’s Purchasing Group Board of Directors, is past recipient of Takeda Pharmaceuticals President’s Award and founded SEEDs Alliance bringing together 600+ biotechnology and pharmaceutical industry stakeholders to green the life sciences.

Altos-Labs-Cheri-Curry

Cheri Curry

VP, Procurement

Dr. Elkes is the VP of Portfolio Management and Business Operations at Altos Labs.&nbsp; He previously led portfolio strategy and planning for Genentech Research and Early Development (gRED), which delivered more than 80 drug candidates into development. He catalyzed gRED 2025, a strategy to propel Genentech research and development into the future. Dr. Elkes helped shepherd the development and commercialization of immunotherapies ipilimumab and nivolumab at Medarex. Additionally, he worked as a Scientist at Exelixis and as a management consultant. Dr. Elkes studied Molecular Biology and Public Policy at Princeton and received his Ph.D. in Genetics at Harvard, and is also known for his work in the movement to end modern day slavery.

Altos-Labs-Dan-Elkes

Dan Elkes

VP, Portfolio Management and Business Operations

Thomas Nollie has experience in the management of projects, personnel, and manufacturing plants that include ship construction and repair, plant management, multi-plant management, and engineering design. Nollie graduated from the United Stated Naval Academy where he received his BS degree. He furthered his education with a MSME, MBA, and Doctorate in Mechanical Engineering. Nollie held roles as Commanding Officer, Business Manager, Repair Officer, Project Officer for new construction of ships, and Chief Design Engineer of repair facilities. He has held positions as VP/General Manager and President/COO.&nbsp;Nollie has most recently held roles as Principal Managing Engineer and Director roles at multiple biotech firms.

Altos-Labs-Thomas-Nollie

Thomas Nollie

VP, Global Engineering and Site Services

VP, Global Facilities and Site Services

Adam is the head of Altos Labs' global transactional law practice. He is an&nbsp;innovative and solution-oriented business partner with&nbsp;deep expertise in corporate, commercial, and intellectual property matters.&nbsp;Prior to joining Altos, Adam spent over 11 years with Illumina where as VP, Legal he negotiated strategic&nbsp;partnerships and led a team of attorneys and contract analysts.&nbsp;He holds a J.D. from the University of San Diego School of Law and a B.S. in Biology with a concentration in molecular biology from Tufts University.

Altos-Labs-Adam-Welland

Adam Welland

VP, Transactions and Partnerships

Dr. Bikash Sabata joined Altos Labs from Roche Diagnostics, where he was the VP of Software Systems at Roche Sequencing Solutions, leading the software development for the sequencing platform. He worked for Roche in several positions, including those of Head of Imaging and Software for Digital Pathology, Head of Advanced Workflow and Analytics, Head of Software for Ariosa Labs (NIPT CLIA Lab in Roche Sequencing), and Head of Architecture for Personalized Health Care (program in Roche Pharma and Genentech).&nbsp;Before joining Roche, Dr. Sabata was the Chief Technology Officer of BioImagene, where he oversaw the development of artificial intelligence (AI) algorithms for digital pathology and led software engineering. Dr. Sabata started his career as an assistant professor of Computer Science at Wayne State University, then moved to SRI International, where he was a Senior Scientist while simultaneously serving as a part-time Research Associate at Stanford University. In addition, he has held positions at multiple startups, including those he helped found, such as Primitive Root and Aginova. His background gives him a wide-ranging viewpoint on the nexus between AI and the life sciences.&nbsp;Dr. Sabata is driven to translate research ideas into marketable products that can change the world. To this end, he draws on his extensive experience and a deep understanding of technology and solutions in the areas of AI/ML, computer vision, medical informatics, omics, medical imaging, digital pathology, and intelligent distributed systems. Dr. Sabata holds a PhD from the University of Texas at Austin with a focus on computer vision and AI/ML.